Depressive Disorder

Depressive disorder, particularly Major Depressive Disorder (MDD), is a widespread and debilitating mental health condition that significantly impacts the quality of life for individuals and their families. It is characterized by persistent low mood, loss of interest or pleasure, and a range of other emotional and physical symptoms. MDD is a common condition, with lifetime prevalence estimated to be around 15%^[1], and is consistently observed to be twice as common in women compared to men ^[2].

The clinical relevance of depressive disorder is profound, contributing to high morbidity and a significant burden of disease globally. It is associated with substantial years lost in productivity^[1]and an increased risk of mortality, including suicide and other health complications. The pervasive nature of its symptoms can interfere with daily functioning, relationships, and overall well-being. Understanding its origins is crucial for developing effective prevention strategies and treatments.

From a biological perspective, depressive disorder is recognized as a complex condition with a significant genetic component. Research indicates that it is highly familial, with early age of onset and recurrent episodes often showing stronger patterns within families. This implied genetic etiology has driven extensive research, including genome-wide association studies (GWAS), to identify specific genetic variants that contribute to vulnerability. Identifying common variants associated with trait depression may not only shed light on this specific condition but also provide insights into shared mood components across a wider range of psychiatric disorders. These genetic findings can point towards biological pathways that may become targets for new, broad-spectrum treatments.

The social importance of addressing depressive disorder cannot be overstated. Its widespread prevalence and debilitating effects place a considerable strain on public health systems and communities. The disorder affects individuals across all demographics, leading to reduced quality of life, increased healthcare costs, and diminished societal participation. Ongoing research into the genetic and biological underpinnings of depression is vital for advancing our understanding, improving diagnostic tools, and ultimately developing more effective and personalized interventions to alleviate suffering and improve outcomes.

Limitations

Research into depressive disorder, particularly through genetic association studies, faces several inherent limitations that influence the interpretation and generalizability of findings. These challenges stem from the complex nature of the disorder, the methodologies employed, and the vast array of contributing factors. Acknowledging these limitations is crucial for understanding the current state of knowledge and guiding future research directions.

Methodological and Statistical Constraints

Current genome-wide association studies (GWAS) primarily focus on common single nucleotide polymorphisms (SNPs), which have been found to explain only a small portion of the variance in depressive disorder, often 1% or less. This suggests that common SNPs with large individual effects are unlikely to be a primary driver of the trait. Consequently, detecting significant associations requires exceptionally large sample sizes, often in the range of 10,000 to 20,000 cases, which many individual studies or smaller meta-analyses have yet to achieve. Underpowered studies are susceptible to the “winner’s curse” effect, where significant findings may overestimate the true genotypic relative risks due to selection bias in smaller samples. Moving forward, the full genetic component of such complex traits necessitates examining other types of variants, such as rare variants and copy number variants, which are not comprehensively captured by current GWAS methodologies and require large-scale sequencing projects for complete genetic coverage.

Phenotypic Heterogeneity and Measurement Challenges

A significant limitation in understanding depressive disorder lies in its inherent genetic and phenotypic heterogeneity. The polygenic model suggests that each affected individual might harbor a unique combination of risk variants, leading to a spectrum of phenotypic symptoms. This complexity makes it challenging to define homogenous subsets for genetic analysis, even when researchers prioritize more heritable and less prevalent subtypes like recurrent early-onset major depressive disorder, as genome-wide significant associations have remained elusive. Furthermore, consistent results have not been yielded by stratification based on factors like sex. Practical challenges also exist in phenotype definition, with accurate delineation of specific subtypes (e.g., typical versus atypical MDD) often unavailable or prohibitively expensive to assess with advanced methods like magnetic resonance imaging^[3]The broad and varied symptom profiles of depressive disorder highlight the need for more nuanced quantitative scores of severity and reliability to balance sample size with phenotype precision.

Unexplored Biological and Environmental Contributions

Despite advances in identifying common genetic variants, a substantial portion of the heritability of depressive disorder remains unexplained, pointing to significant knowledge gaps beyond common SNPs. A comprehensive understanding requires investigating other biological mechanisms that contribute to the disorder’s etiology. Specifically, the role of epigenetic effects, such as DNA methylation and histone modifications, is complex and requires the development of new methods for full biological evaluation. Similarly, environmental factors are known to contribute significantly to psychiatric disorders, yet their interplay with genetic predispositions—gene-environment interactions—is not fully explored by current research designs. Addressing these missing components is crucial for developing a complete etiological model and effective interventions for depressive disorder.

Variants

The genetic landscape of depressive disorder involves a complex interplay of numerous genes and their variants, influencing various biological pathways from synaptic function to cellular stress responses and neurotransmitter signaling. Understanding these variants provides insight into individual susceptibility and the heterogeneous nature of the disorder.

Variants in genes critical for synaptic plasticity and neuronal connectivity are central to the biology of depression. For instance, PTPRD (Protein Tyrosine Phosphatase, Receptor Type D), through its role in regulating tyrosine phosphorylation, is essential for the development and function of glutamatergic synapses, which are fundamental to learning, memory, and mood regulation. The variant rs1853229 in PTPRD may influence the expression or activity of this phosphatase, thereby altering synaptic strength and neuronal connectivity. Similarly, LRFN5-DT (Leucine Rich Repeat And Fibronectin Type III Domain Containing 5 - Antisense Transcript), an antisense non-coding RNA, is thought to regulate the expression of LRFN5, a gene vital for excitatory synapse formation and maintenance. The variant rs11157241 in LRFN5-DT could modulate this regulatory process, impacting the integrity and function of neural networks involved in mood. Furthermore, SWAP70 (SWAP70 Homolog, B-Cell Activation Associated) is involved in organizing the actin cytoskeleton and cell migration, processes essential for neuronal plasticity and dendritic spine remodeling. The variant rs570665128 could subtly alter SWAP70’s function, potentially affecting the brain’s ability to adapt and form new connections, which is often impaired in depressive states.

Other variants influence key neurotransmitter systems, lipid metabolism, and cellular detoxification. The DRD2 (Dopamine Receptor D2) gene encodes a key receptor in the brain’s reward and motivation pathways, profoundly influencing mood, cognition, and motor control. The variant rs4936272 in DRD2 may affect the receptor’s expression levels or sensitivity to dopamine, thereby altering the strength of dopaminergic signaling. Since reduced reward sensitivity and anhedonia are core symptoms of depression, such variants could significantly impact an individual’s vulnerability. PLA2G2C (Phospholipase A2 Group IIC) is an enzyme involved in lipid metabolism and the generation of inflammatory mediators. The variant rs531450121 could influence PLA2G2Cactivity, impacting neuroinflammatory processes and lipid signaling pathways within the brain. Given the growing evidence linking neuroinflammation to the pathophysiology of depressive disorder, this variant may play a role in modulating the brain’s inflammatory state. Additionally,CBR3-AS1 (Carbonyl Reductase 3 - Antisense RNA 1) is a non-coding RNA that likely regulates CBR3, an enzyme critical for metabolizing various carbonyl compounds, including neurosteroids, and influencing cellular redox balance. The variant rs138801403 in CBR3-AS1could alter this regulatory interaction, potentially affecting cellular detoxification, steroid hormone levels, or oxidative stress responses, all of which are implicated in the etiology of mood disorders.

Beyond direct synaptic and neurotransmitter effects, variants also impact fundamental cellular processes, including stress responses, protein homeostasis, and transcriptional regulation. MAD1L1 (Mitotic Arrest Deficient 1 Like 1), primarily known for its role in cell division, also contributes to neuronal development and survival. The variant rs11763750 in MAD1L1 might influence its expression or function, potentially impacting cellular stress responses or the delicate balance of neurogenesis and neuronal survival, which are relevant to the brain’s resilience in the face of depressive illness. FAM177A1 (Family With Sequence Similarity 177 Member A1) is involved in cellular stress responses and DNA repair mechanisms. The variant rs553807001 in FAM177A1could subtly alter these fundamental cellular processes, affecting how neurons cope with various stressors that contribute to the development or exacerbation of depressive symptoms.KLHDC8B (Kelch Domain Containing 8B), a protein involved in protein-protein interactions and likely protein degradation pathways, plays a role in maintaining cellular homeostasis. The variant rs9586 in KLHDC8B could influence these pathways, potentially affecting the removal of misfolded proteins or the regulation of signaling molecules crucial for neuronal health. Finally, the region encompassing RN7SKP19 - LINC01360 (RNA, 7SK Small Nuclear Pseudogene 19 - Long Intergenic Non-Coding RNA 01360) involves non-coding RNAs that are often critical regulators of gene expression. The variant rs12140625 within this region could impact transcriptional control, subtly altering the expression of genes vital for neuronal function and the brain’s overall ability to regulate mood.

Key Variants

RS ID	Gene	Related Traits
rs553807001	FAM177A1	depressive disorder
rs531450121	PLA2G2C	depressive disorder
rs570665128	SWAP70	depressive disorder
rs11157241	LRFN5-DT	major depressive disorder depressive disorder
rs11763750	MAD1L1	sleep duration trait suicidal ideation, suicide behaviour depressive disorder
rs4936272	DRD2	major depressive disorder depressive disorder
rs12140625	RN7SKP19 - LINC01360	chronic obstructive pulmonary disease depressive disorder
rs9586	KLHDC8B	feeling miserable measurement endometriosis, major depressive disorder mood disorder, major depressive disorder depressive disorder
rs1853229	PTPRD	depressive disorder
rs138801403	CBR3-AS1	depressive disorder

Depressive Disorder: Classification, Definition, and Terminology

Major depressive disorder (MDD) is a common psychiatric condition characterized by significant impairments in daily functioning and a cluster of specific symptoms uring disposition can increase vulnerability to depressive states and may be a common factor underlying comorbidities among various psychiatric disorders.

Diagnostic Tools Diagnostic instruments such as the World Health Organization Composite International Diagnostic Interview Short Form (CIDI-SF) are used in research and clinical settings .

Typical Presentations

Depressive disorder is primarily characterized by its psychic components, which include core aspects of depressed mood^[4]. Individuals may experience susceptibility to feelings of sadness, hopelessness, worthlessness, discouragement, guilt, and loneliness ^[4]. While the characteristic psychic components are central, physical symptoms are typically not encompassed in the assessment of the depression facet ^[4]. Different presentations, such as typical versus atypical major depressive disorder, exist, though their precise delineation can be challenging^[5]. Some studies specifically exclude patients with psychotic depression, indicating it as a distinct, more severe presentation.

Measurement Approaches

Trait depression is commonly assessed using standardized instruments like the English and Italian versions of the Revised NEO Personality Inventory (NEO-PI-R) ^[4]. The Depression scale within this inventory consists of eight items, including two reverse-scored items to mitigate acquiescence bias ^[4]. Responses are typically gathered using a five-point Likert scale, ranging from “strongly disagree” to “strongly agree.” Scores are often standardized, for example, to a mean of 50 and a standard deviation of 10, using norms from combined gender populations ^[4]. To enhance reliability and robustness of personality score estimates, especially for traits considered stable over time, multiple assessments may be averaged across various time points ^[6]. This approach helps reduce variability caused by temporary effects and random error. The use of quantitative scores for severity and reliability is considered an effective strategy for defining phenotypes ^[5].

Variability

Depressive disorder can manifest with a spectrum of phenotypic symptoms, consistent with a polygenic model where each affected individual might harbor a different combination of risk variants^[3]. Neuroticism, a broader personality dimension reflecting a tendency to experience a wide range of negative emotions, is composed of several lower-order facets, including depression, anxiety, hostility, self-consciousness, impulsivity, and vulnerability to stress^[4]. The depression facet itself represents an enduring disposition that increases vulnerability to depressive states and may contribute to comorbidities among psychiatric disorders.

There is significant genetic heterogeneity in major depressive disorder. Studies suggest that women face a two-fold increased risk, and genetic risk factors may operate partially independently for women and men^[7]. Depression scores can vary widely among individuals and across different study populations; for instance, scores in one sample ranged from 29 to 86 (mean = 54, standard deviation = 9), while in another, they ranged from 27 to 86 (mean = 48, standard deviation = 10). While personality traits are generally stable over time, individual symptom profiles for major depressive disorder can vary.

Causes

The understanding of the underlying causes (etiology) of depressive disorder, also known as Major Depressive Disorder (MDD), is still developing^[8]. However, research highlights both genetic and environmental factors that contribute to its development.

Genetic Factors

Depressive disorder is recognized as familial, meaning it tends to run in families^[8]. The heritability of the condition is estimated to be 0.37, indicating that approximately 37% of the variation in susceptibility to MDD can be attributed to genetic factors ^[8]. A higher degree of familial aggregation, where multiple family members are affected, is associated with both an earlier age of onset and recurrent episodes of depression ^[8].

Studies aiming to identify specific genetic variants linked to MDD suggest that common single nucleotide polymorphisms (SNPs) with large effects on depression are unlikely to exist^[8]. Instead, variants identified so far explain only a small fraction of the variance, typically 1% or less ^[8]. A more complete understanding of the genetic component will likely require examining other types of genetic variations, such as rare variants and copy number variants ^[8]. Large-scale sequencing projects are considered a necessary approach to achieve comprehensive genetic coverage and assess the impact of these rarer variants ^[8].

Genome-wide association (GWA) studies can identify common variants that contribute to traits and diseases, even those with small individual effects, by pointing to genes that might harbor rarer variants with larger impacts or by elucidating biological pathways ^[8]. There is also increasing evidence that various psychiatric disorders may share common genetic loci, suggesting that common genetic variants associated with psychiatric conditions in clinical studies can contribute to depression ^[8]. The biological pathways involving these shared genetic loci could represent targets for developing broader treatments effective across a range of mental health conditions ^[8]. Focusing on “trait depression,” a more specific aspect of personality, as a narrower phenotype may increase the statistical power in genetic association studies and provide insights into a wider array of psychiatric disorders that involve a mood component ^[8].

Environmental Factors

Environmental factors play a role in the development of psychiatric disorders ^[8]. Researchers are also investigating epigenetic effects, which involve changes in gene expression without altering the underlying DNA sequence ^[8]. Epigenetic mechanisms like DNA methylation, histone modifications, DNA rearrangement, and RNA inhibition have been implicated in complex behaviors and psychiatric disorders^[8]. However, the role of these epigenetic phenomena is intricate and requires new methods to fully evaluate the biological mechanisms contributing to complex disorders ^[8].

A greater understanding of MDD’s causes may be gained by studying individuals exposed to clearly defined environmental events, such as women experiencing perinatal and postpartum depression ^[8]. Ultimately, a comprehensive understanding of MDD’s etiology will necessitate prospective, longitudinal studies that broadly characterize individuals both phenotypically and genetically, allowing for the combined analysis of genetic and environmental influences ^[8].

Biological Background

Major depressive disorder (MDD) is a complex condition influenced by biological factors. Research indicates a significant genetic component, with MDD being familial and having a heritability estimated around 0.37^[7]. This genetic predisposition has driven investigations into specific genetic variants and the underlying molecular and cellular pathways involved ^[9].

Molecular Neurobiology

The molecular neurobiology of depression is an active area of study, exploring the intricate cellular processes and signaling pathways that contribute to the disorder ^[10]. Understanding these pathways is critical for developing broad-spectrum treatments.

Epigenetic Regulation

Epigenetics, the study of heritable changes in gene expression that do not involve changes to the underlying DNA sequence, plays a role in psychiatric disorders, including MDD ^[11]. Molecular studies of MDD have increasingly adopted an epigenetic perspective to understand its etiology ^[12]. These epigenetic mechanisms can influence how genes are turned on or off, potentially affecting brain function and vulnerability to depression.

Specific Genes and Pathways

One gene implicated in neurological function is Sp4, which belongs to the Sp1-family of zinc finger transcription factors ^[13]. Sp4 is essential for normal development, viability, and fertility in mice ^[14]. Reduced expression of the Sp4 gene in mice has been linked to deficits in sensorimotor gating and memory, along with hippocampal vacuolization ^[15]. This suggests that Sp4may play a role in brain processes relevant to MDD. Additionally, non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways are also areas of biological investigation^[16].

Pathways and Mechanisms

Depressive disorder involves a complex interplay of molecular and physiological mechanisms within the brain. Research indicates several key pathways and components contribute to its development and manifestation.

One significant area of investigation focuses on glutamate signaling. Metabotropic glutamate receptors (mGluRs) are implicated in the regulation of mood disorders^[17]. The activation of glutamate receptors can also lead to the calpain-mediated degradation of Sp3 and Sp4, which are prominent Sp-family transcription factors found in neurons^[18].

Transcription factors, particularly those belonging to the Sp-family, play a role in these mechanisms ^[13]. For instance, Sp4, a zinc finger transcription factor, is crucial for normal murine growth, viability, and male fertility. Studies have shown that reduced expression of the Sp4 gene in mice results in deficits in sensorimotor gating and memory, accompanied by hippocampal vacuolization ^[14]. Additionally, non-classical genomic estrogen receptor (ER) signaling pathways, which involve specificity protein and activating protein-1, are relevant^[16].

Epigenetic mechanisms are increasingly recognized for their contribution to psychiatric disorders. Molecular studies of major depressive disorder have explored an epigenetic perspective, highlighting changes in gene expression that do not involve alterations to the underlying DNA sequence^[12].

Furthermore, selective microRNAs (miRNAs) and their effectors are considered common long-term targets for interventions aimed at modulating mood ^[15].

The molecular neurobiology of depression remains a critical and active area of scientific inquiry ^[10].

Pharmacogenetics

Pharmacogenetics for depressive disorder explores how an individual’s genetic makeup may influence their response to antidepressant medications. The Sequenced Treatment Alternatives to Relieve Depression (STARD) study, a large-scale research initiative, was designed to evaluate various treatment options for individuals with major depressive disorder^[19]. Genetic analyses conducted within cohorts like STARD have contributed to the identification of novel genetic loci associated with major depression ^[9].

Frequently Asked Questions About Depressive Disorder

These questions address the most important and specific aspects of depressive disorder based on current genetic research.

---

1. If depression runs in my family, am I doomed to get it too?

Not necessarily. While depressive disorder is highly familial, meaning it often runs in families, genetics only explain a portion of the risk. Many factors, including your environment and life experiences, also play a significant role. It means you might have a higher predisposition, but it’s not a guarantee.

2. My sibling struggles with depression, but I don’t. Why are we so different?

Even within families, people can have different genetic predispositions and life experiences. Depressive disorder is polygenic, meaning many genes with small effects contribute, so you and your sibling could have inherited different combinations of risk variants. Environmental factors and individual resilience also play a huge part.

3. Can a DNA test tell me if I’ll get depression?

Currently, DNA tests can’t definitively predict if you will get depression. While research has identified some common genetic variants associated with depressive disorder, these variants explain only a very small portion (often 1% or less) of the overall risk. The disorder is complex, involving many genes and environmental factors.

4. Why does my depression feel so different from my friend’s, even if we both have it?

Depressive disorder is very heterogeneous, meaning it presents differently in different people. You and your friend likely have unique combinations of genetic risk factors and individual life experiences that shape your specific symptoms and severity. Researchers are still working to understand these distinct subtypes.

5. Does my lifestyle even matter if depression is partly genetic?

Absolutely, your lifestyle matters immensely! While genetics contribute to a predisposition, environmental factors and your daily habits interact with your genes. Things like stress management, social support, and healthy routines can significantly influence whether depression develops or how severely it affects you.

6. Is it true that women are just more prone to depression genetically?

Depressive disorder is observed to be twice as common in women, but the precise genetic reasons for this difference are still being actively researched. While there are biological differences, current genetic studies haven’t consistently identified specific genetic variations that solely explain this higher prevalence in women. It’s likely a complex interplay of biology, hormones, and societal factors.

7. Does experiencing a lot of stress make me more likely to get depressed?

Yes, stress is a significant environmental factor. For individuals with a genetic predisposition, the interplay between their genes and stressful life events (gene-environment interaction) can increase their vulnerability to developing depression. However, this interaction is complex and not yet fully explored by current research.

8. Why do some people seem to get depressed more easily than others?

People have different levels of genetic vulnerability. Some individuals might inherit a combination of many small genetic risk factors that make them more susceptible to depression when faced with life stressors or other environmental triggers. Others might have more protective genetic profiles.

9. Can understanding my genes help my doctor treat my depression better?

In the future, yes. Current genetic research is helping to identify biological pathways involved in depressive disorder, which could lead to new, broad-spectrum treatments. While not yet routine, personalized medicine based on genetic insights is a promising area for more effective and targeted interventions.

10. I’ve always struggled with depression. Will my children definitely inherit it?

Not definitely. While there is a significant genetic component and depression can run in families, it doesn’t mean your children will automatically inherit it. They may inherit some genetic predispositions, but whether they develop the disorder also depends on their unique environment, life experiences, and other biological factors.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Murray, C. J., and A. D. Lopez. “Evidence-based health policy–lessons from the Global Burden of Disease Study.”Science, vol. 274, 1996, pp. 740–743.

[2] American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., American Psychiatric Association, 1994.

[3] Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. American Journal of Psychiatry, 2000 Oct, 157(10), 1552–1562.

[4] Costa, Paul T., and Robert R. McCrae. Revised NEO Personality Inventory (NEO PI-R) and NEO Five-Factor Inventory (NEO-FFI) Professional Manual. Psychological Assessment Resources, 1992.

[5] Hettema, John M., et al. “Genetic epidemiology of anxiety disorders.”Annual Review of Clinical Psychology, vol. 4, 2008, pp. 375–397.

[6] Costa, Paul T., and Robert R. McCrae. “Personality in adulthood: A six-year longitudinal study of self-reports and spouse ratings on the NEO Personality Inventory.” Journal of Personality and Social Psychology, vol. 54, no. 5, 1988, pp. 853–863.

[7] Kendler, Kenneth S., et al. “A population-based twin study of major depression in women: The impact of perceived parental care.” Archives of General Psychiatry, vol. 49, no. 12, 1992, pp. 936–942.

[8] Wray, N. R., et al. “Genome-wide association of trait depression.” Molecular Psychiatry, 2010.

[9] Shyn, S. I., et al. “Novel Loci for Major Depression Identified by Genome-Wide Association Study of Sequenced Treatment Alternatives to Relieve Depression and Meta-Analysis of Three Studies.” Molecular Psychiatry, 29 Dec. 2009, e-pub ahead of print.

[10] Krishnan, V., and E. J. Nestler. “The molecular neurobiology of depression.” Nature, vol. 455, no. 7215, 16 Oct. 2008, pp. 894–902.

[11] Tsankova, N., et al. “Epigenetic regulation in psychiatric disorders.” Nat Rev Neurosci, vol. 8, 2007, pp. 355–367.

[12] Mill, J., and A. Petronis. “Molecular studies of major depressive disorder: the epigenetic perspective.”Mol Psychiatry, vol. 12, 2007, pp. 799–814.

[13] Suske, G. “The Sp-family of transcription factors.” Gene, vol. 238, no. 2, 1 Oct. 1999, pp. 291–300.

[14] Supp, D. M., et al. “Sp4, a Member of the Sp1-Family of Zinc Finger Transcription Factors, Is Required for Normal Murine Growth, Viability, and Male Fertility.” Developmental Biology, vol. 176, no. 2, 15 June 1996, pp. 284–299.

[15] Zhou, X., et al. “Reduced expression of the Sp4 gene in mice causes deficits in sensorimotor gating and memory associated with hippocampal vacuolization.” Mol Psychiatry, vol. 10, no. 4, 23 Nov. 2004, pp. 393–406.

[16] Safe, S., and K. Kim. “Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways.”J Mol Endocrinol, vol. 41, no. 5, 2008, pp. 263–275.

[17] Pilc, A., Chaki, S., Nowak, G., and Witkin, J. M. “Mood disorders: Regulation by metabotropic glutamate receptors.”Biochemical Pharmacology, vol. 75, no. 5, 2008 Mar 01, pp. 997–1006.

[18] Mao, X., Moerman-Herzog, A. M., Wang, W., and Barger, S. W. “Glutamate receptor activation evokes calpain-mediated degradation of Sp3 and Sp4, the prominent Sp-family transcription factors in neurons.”J Neurochem, vol. 100, no. 5, 2007 Mar, pp. 1300–1314.

[19] Fava, Maurizio, et al. “Background and Rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study.” Psychiatric Clinics of North America, vol. 26, no. 2, June 2003, pp. 457–494.